- Home
- LIQT vs BLRX Comparison
LIQT vs BLRX Comparison
Compare LIQT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIQT | BLRX |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | Denmark | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 12.6M |
| IPO Year | 2011 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LIQT | BLRX |
|---|---|---|
| Price | $2.10 | $2.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.30 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 19.4K | 19.2K |
| Earning Date | 05-13-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.12 | N/A |
| Revenue Next Year | $63.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $2.15 |
| 52 Week High | $3.35 | $7.77 |
Technical Indicators
Market Signals| Indicator | LIQT | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 64.79 |
| Support Level | $2.19 | $2.66 |
| Resistance Level | $2.56 | $3.11 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 75.44 | 83.56 |
Price Performance
Historical ComparisonAbout LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in businesses that are liquid filtration market and the silicon carbide ceramic membrane & diesel particulate filter (DPF) market. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and others. Its operating segment includes Water, Ceramics, and Plastics.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.